Pharmaceutical Executive
March 11, 2020
Features
40
3
Exploring the challenge for pharma in adapting multichannel marketing strategies for the global stage, while trying to refine messages and communicate a brand identity to multiple local audiences.
March 11, 2020
Columns
40
3
Examining the key learnings from BCG’s 2019 benchmark study-and the capabilities uncovered that will be critical to future performance.
March 11, 2020
From the Editor
40
3
Amid concerns over a potential 'wild west' climate for data analytics in pharma, taking a long-term, proactive, and enterprise view of your company’s data may be the best way to keep your organization and reputation safe.
March 10, 2020
Features
40
3
How to capitalize on the rise of omnichannel engagement in pharma and pursue myriad modes of message delivery in today’s digital world.
March 09, 2020
Columns
40
3
Initiatives aim to limit the gamesmanship that can inhibit prescribing of follow-on biologics.
March 09, 2020
Columns
40
3
The collection of source plasma for new therapies igniting debate.
March 08, 2020
Features
40
3
A look at the ongoing barriers and opportunities in building connections between HCPs, patients, and pharma through social media.
March 07, 2020
Features
40
3
AstraZeneca’s Habib Bennaceur talks about the key transitions in his career-from local to global-and his current role in positioning AZ’s Farxiga as a drug with the potential to impact the lives of both patients with and without type 2 diabetes.
March 01, 2020
Columns
40
3
Approach for pharma field sales reps in need of reboot.
March 01, 2020
Issue PDF
40
3
Click the title above to open the Pharmaceutical Executive March 2020 issue in an interactive PDF format.
March 01, 2020
Special Sponsored Section
40
3
With an estimated annual growth rate of 10%, the Middle East is now consistently outpacing traditionally sought-after “pharmerging” heavyweights such as China and Brazil. The United Arab Emirates is at the center of this newfound momentum-asserting its own credentials as a prospective destination for big-ticket foreign investment in healthcare.